Intensive Chemotherapy Vs. Azacitidine + Venetoclax for AML with Secondary Mutations

Introduction

In AML, secondary mutations (sMut) represent a group of mutations with a strong association with clinically-defined secondary AML (sAML). AML with sMut have been associated with inferior survival outcomes and have been incorporated into the updated ELN 2022 guidelines to reflect high-risk disease as AML with myelodysplasia-related gene mutations (AML-MR). Prior studies have demonstrated improved survival outcomes within AML-MR with the utilization of hypomethylating agents and venetoclax (HMA+Ven) versus hypomethylating agent monotherapy. At present, treatment-specific outcomes, including the benefit of using intensive chemotherapy (IC) versus venetoclax-based regimens, within this cohort remain understudied.

Methods

This study included patients diagnosed with AML harbouring sMut, first seen at PMCC from 1^st Jan 2015 to April 2023. Patients were excluded from the analysis if the NGS data was unavailable or if it was performed >6 months from time of diagnosis. sMut included mutations within one or more of the following genes: SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, or STAG2. Non-intensive therapy included patients treated with HMA monotherapy and venetoclax-based regimens in the first line setting. The primary objective was to compare IC with with venetoclax-based regimens within AML with sMut. A key secondary objective was to evaluate the role of allogeneic hematopoetic stem cell transplant (HSCT) in patients with AML with sMut.

OS was calculated from date of AML diagnosis to date of last known follow up or date of death. Kaplan-Meier survival curves were generated for OS, and differences were tested using the log-rank test.

Results

A total of 665 patients were eligible for inclusion in this study with, a median follow-up of 12.39 (0.03, 108.3) months. 418 (63%) patients had de novo AML, 186 (30%) patients had an antecedent hematologic malignancy, and 51 (8%) AML had a history of cytotoxic therapy. Of the total study population, 364 (68%) patients received IC,168 (32%) patients received non-intensive chemotherapy of which 87 (17%) received HMA+Ven. Patients treated with HMA+Ven were significantly older (76.1 vs 62.7, p=<0.0001) and were less likely to have an NPM1 mutation (14% vs 17%, p=0.047). There was no significant difference in cytogenetic risk (p=0.45), TP53 status (p=0.56), or FLT3-ITD status (p=0.05). Patients with de novo AML had improved OS compared to patients with sAML and tAML with sMut (3-year OS 39.5% vs 19.9% vs 23.2%, p= <0.0001).

The primary analysis of IC vs. HMA-Ven was restricted to patients 70 years old and younger to minimize bias by including only patients who would theoretically be eligible for treatment with curative intent. When comparing these patients with newly diagnosed AML with sMut who were 70 years old at diagnosis or younger, there was no significant difference in OS between those who received upfront IC vs. HMA-Ven (3-year OS 52.8% vs 48.9%, p=0.25).Among patients less than 70 years old at diagnosis who received IC, patients who underwent HSCT had significantly improved OS compared to those who did not undergo HSCT (p= <0.0001). There was no statistically significant difference in OS between patients who received IC versus HMA+Ven prior to transplant (p=0.0756).

In multivariable analysis (MVA), NPM1 mutation was associated with improved OS (aHR 0.63 [0.43, 0.92]). Patients who did not undergo HSCT (aHR 3.13 [2.35, 4.18]), had sAML (aHR 1.32, [1.01, 1.73]), tAML (aHR 1.52 [1.01, 2.30]), or high-risk cytogenetics (aHR 3.03, [1.29, 7.13]) had inferior OS in MVA. There was no significant difference in OS in patients receiving IC versus HMA+Ven (p=0.055) after adjustment for confounding variables.

Conclusions

AML-MR represents a novel, high-risk entity with recent introduction into ICC and WHO guidelines and has been associated with inferior survival outcomes emphasizing the importance of investigating treatment-specific outcomes. When comparing IC to HMA+Ven in patients with AML and sMut up to the age of 70 years, there was no significant improvement in OS. We also found that patients with AML and sMUT who received HSCT had improved OS compared to those treated with IC alone. A limitation of this study includes potential bias from clinical factors including comorbidities and frailty that may have influenced treatment candidacy and will be addressed in future studies including matched-cohort analyses.

Chan:Servier Pharmaceuticas LLC: Research Funding. Gupta:Pfizer: Consultancy, Other: Participation on a data safety or advisory board; Sumitomo Pharm: Consultancy; BMS/Celgene: Consultancy, Other: Participation on a data safety or advisory board; Daiichi Sankyo: Consultancy, Other: Participation on a data safety or advisory board; Incyte: Consultancy, Other: Participation on a data safety or advisory board; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Sierra Oncology: Consultancy, Other: Participation on a data safety or advisory board; Novartis: Consultancy; Constellation: Consultancy; GSK: Consultancy, Honoraria, Other: support for attending meetings and/or travel; CTI Biopharma: Consultancy, Other: Participation on a data safety or advisory board; Roche: Membership on an entity's Board of Directors or advisory committees. Richard-Carpentier:BMS: Other: Advisory Board Participation; AbbVie: Honoraria, Other: Advisory Board Participation; Taiho: Honoraria, Other: Advisory Board Participation; Astellas: Honoraria, Other: Advisory Board Participation; Pfizer: Honoraria, Other: Advisory Board Participation. Schimmer:BMS: Research Funding; UHN: Patents & Royalties: DNT cells; Otsuka Pharmaceuticals: Consultancy; Takeda: Consultancy, Research Funding; Medivir AB: Research Funding; Novartis: Consultancy; Jazz: Consultancy. Yee:Astex: Other: research support; Forma Therapeutics: Other: research support; F. Hoffmann-La Roche: Other: research support; Genentech: Other: research support; Geron: Other: research support; Gilead Sciences: Other: research support; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: research support; Bristol Myers Squibb/Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Membership on an entity's Board of Directors or advisory committees; Jazz: Membership on an entity's Board of Directors or advisory committees; Shattuck Labs: Membership on an entity's Board of Directors or advisory committees; Taiho Pharma: Membership on an entity's Board of Directors or advisory committees; Taiho Pharma: Honoraria. Maze:Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene/BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pharma Essentia: Research Funding; Takeda: Research Funding; Kronos Bio: Research Funding; Jazz: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy.